Navigation Links
Breast Cancer Message Barred in Eli Lilly's Hometown
Date:11/3/2010

SAN FRANCISCO, Nov. 3, 2010 /PRNewswire-USNewswire/ --Breast Cancer Action (BCA) learned today that its efforts to deliver a message to Eli Lilly & Company via a billboard in Indianapolis have been blocked.  The message:  "Eli Lilly is making us sick.  Tell them to stop" was rejected by every billboard company in Indianapolis, Lilly's hometown.

Despite working within the guidelines of each billboard company contacted, the advocacy group has been turned down because of the content of the message.  At a time when political advertizing across the nation has reached an all time high, the rejection of BCA's message raises critical questions about who controls the media when it comes to public health.

"We are talking about women's health here.  A breast cancer organization's message about the impact of a drug company's behavior is being kept off billboards in the company's home town.  When corporate influence runs this deep, the public should be outraged. We certainly are," said BCA executive director Barbara Brenner.

The public's health is at stake.  Eli Lilly is the sole worldwide manufacturer of rBGH (recombinant bovine growth hormone also known as rBST) which is sold under the name Posilac and has long been linked to cancer.  The artificial hormone is given to dairy cows to stimulate milk production.

Breast Cancer Action's "Milking Cancer" campaign demands Eli Lilly stop manufacturing the artificial stimulant rBGH.  In September 2010, signatures were gathered from over 6,732 individuals—one for each day that rBGH has been on the market—committed to delivering a message to Eli Lilly via a billboard in Indianapolis. For more information see www.milkingcancer.org.

Breast Cancer Action is a non-profit education and advocacy organization that does not accept funding from pharmaceutical companies or any other organizations that profit from or contribute to the breast cancer epidemic.


'/>"/>
SOURCE Breast Cancer Action
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CyberKnife Radiosurgery for Early-Stage Breast Cancer
2. 10 Tips for Breast Cancer Survivors
3. Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
4. 10 Tips for Breast Cancer Screening and Early Detection
5. Jefferson Radiology Becomes First Diagnostic Imaging Group in Connecticut to Add Automated Ultrasound Capability for Screening Women with Dense Breast Tissue
6. Alma Lasers Joins the Fight Against Breast Cancer with the Launch of the NEW SopranoXLi
7. SightLine Health Adds Naviscan PEM Technology to Breast Cancer Treatment Services
8. FUJIFILM Revitalizes Images of Health Breast Cancer Awareness Initiative
9. FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
10. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
11. Swiss Breast Cancer Patient Becomes First in World to Receive Treatment Using Gated RapidArc from Varian Medical Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):